Overview
GRAIL develops multi-cancer early detection blood tests, including the Galleri test, designed to detect more than 50 types of cancer from a single blood draw using next-generation sequencing.
Latest industry news
BioNTech Veterans Land $25M Seed Round to Build AI-Powered Cancer Surveillance Platform
2026-10-19 · Funding
Rapid DNA Testing Rolls Out at Arkansas County Jails, With More Sites on the Way
2026-10-18 · Industry
GenePlanet Secures Strategic Investment from Lauxera, Setting Sights on Unicorn Status
2026-10-17 · Funding
St. Luke's Cancer Genomics Service Signals a New Era for Precision Oncology in the Philippines
2026-10-16 · Industry
Company details
Category
🧬 Clinical Diagnostics | Oncology Genomics
Location
Menlo Park, California, USA
Funding
Acquired by Illumina in 2021; previously raised over $1.9 billion in private funding including Series B and Series D rounds
Website
grail.comListed
2026-10-19
Is this your company?
Claim this listing to add your logo, full description, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach genomics professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →